Symbiotic Rebrands From Restaking to "Collateral Markets" With Core V2 Launch

The Paradigm- and Pantera-backed protocol says its Wednesday upgrade formalizes a pivot from securing networks to pooling shared collateral for lending, insurance and tokenized assets — a shift built on the protocol's own claims.

Symbiotic launched Core V2 on Wednesday, an upgrade the protocol describes as its official move out of restaking and into what it calls "collateral markets," according to reporting from The Block, which spoke with a company representative.

The pitch, per Symbiotic's announcement: instead of every DeFi application — insurance pools, credit protocols, real-world-asset (RWA) vaults — locking up its own isolated pile of capital, they can share a common collateral base. Each vault sets its own risk parameters, allocation limits, accepted collateral types and loss conditions, enforced onchain. When capital isn't actively backing an obligation, Symbiotic says it can be routed into lending protocols such as Aave and Morpho to earn a base yield, then automatically recalled when an obligation arises.

Symbiotic told The Block that pooling collateral this way is "reportedly" 70% more capital-efficient than standalone liquidity pools — a figure that comes from the protocol itself, with no methodology disclosed.

The first product on Core V2 is Liquid Lane, introduced last month, which the company says lets holders swap tokenized funds, private credit and other RWAs for stablecoins near-instantly rather than waiting out redemption windows that can stretch months. Symbiotic named Midas as Liquid Lane's first issuer, with $6 billion asset manager Fasanara Capital — behind the tokenized credit fund mGLOBAL — as initial curator, and onchain manager KPK joining as a vault curator. Nexus Mutual and Cap are cited as planned users for insurance capacity and institutional credit guarantees, respectively. Nexus Mutual founder Hugh Karp told The Block the shared-collateral model lets "delegated capital sit behind Nexus Mutual as reinsurance capacity."

Symbiotic raised a $29 million Series A in April 2025 led by Pantera, with Coinbase Ventures and 100-plus angels including individuals from Aave, Polygon and StarkWare, plus a $5.8 million seed co-led by Paradigm and cyber.Fund.

Key facts

• Core V2 launched Wednesday, framed as Symbiotic's official pivot from restaking to collateral markets (The Block, citing a Symbiotic rep).
• Claimed 70% capital-efficiency gain vs. standalone pools — Symbiotic's own figure, unverified (The Block).
• Liquid Lane first product; Midas first issuer, Fasanara Capital ($6B AUM) initial curator, KPK a curator (The Block).
• Funding: $29M Series A (April 2025, led by Pantera); $5.8M seed (co-led by Paradigm, cyber.Fund) (The Block).

The real-world read

This is a launch announcement, and nearly every substantive claim traces to Symbiotic or its named partners — not to independent testing. The 70% efficiency number is the protocol's own, hedged with "reportedly" even by The Block, and no methodology is shown; treat it as marketing until someone verifies it. The named users — Nexus Mutual, Cap, Fasanara — are partners with an interest in the platform succeeding, so Karp's endorsement is a customer's, not a neutral assessment. Worth noting the pattern: "restaking," the category Symbiotic is now distancing itself from, was itself last cycle's buzzword. The mechanics (recallable capital, onchain loss conditions) are concrete; whether pooled collateral holds up when multiple vaults face simultaneous losses is exactly what a press release won't tell you.

Opinion, and whose

• Symbiotic (via its representative): V2 makes the collateral-markets shift "official" and is the protocol's forward focus.
• Hugh Karp, Nexus Mutual founder: shared collateral is "especially important for onchain cover," letting Nexus offer "deeper, enforceable cover."

Sources

• The Block (Tier 2, secondary), Daniel Kuhn, 2026-07-01 — sole source; provided launch details, funding history and partner quotes, itself sourced from a Symbiotic representative and the protocol's announcement. Note: The Block discloses Foresight Ventures as majority investor. All product and efficiency claims originate with Symbiotic's own marketing.

This is news reporting, not financial advice.